120 related articles for article (PubMed ID: 29023715)
1. A new parameter of growth inhibition for cell proliferation assays.
Fiorentino FP; Bagella L; Marchesi I
J Cell Physiol; 2018 May; 233(5):4106-4115. PubMed ID: 29023715
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
[TBL] [Abstract][Full Text] [Related]
3. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
4. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
5. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
6. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
[TBL] [Abstract][Full Text] [Related]
7. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy.
Kondo J; Inoue M
Cells; 2019 May; 8(5):. PubMed ID: 31108870
[TBL] [Abstract][Full Text] [Related]
8. What role could organoids play in the personalization of cancer treatment?
Francies HE; Garnett MJ
Pharmacogenomics; 2015; 16(14):1523-6. PubMed ID: 26485224
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week.
Hu Y; Sui X; Song F; Li Y; Li K; Chen Z; Yang F; Chen X; Zhang Y; Wang X; Liu Q; Li C; Zou B; Chen X; Wang J; Liu P
Nat Commun; 2021 May; 12(1):2581. PubMed ID: 33972544
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
Liu F; Wang B; Wang Q; Qi Z; Chen C; Kong LL; Chen JY; Liu X; Wang A; Hu C; Wang W; Wang H; Wu F; Ruan Y; Qi S; Liu J; Zou F; Hu Z; Wang W; Wang L; Zhang S; Yun CH; Zhai Z; Liu J; Liu Q
Oncotarget; 2016 Jul; 7(29):45562-45574. PubMed ID: 27322145
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
12. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
13. Preliminary in vitro evaluation of the anti-proliferative activity of guanylhydrazone derivatives.
França PH; Da Silva-Júnior EF; Aquino PG; Santana AE; Ferro JN; De Oliveira Barreto E; Do Ó Pessoa C; Meira AS; De Aquino TM; Alexandre-Moreira MS; Schmitt M; De Araújo-Júnior JX
Acta Pharm; 2016 Mar; 66(1):129-37. PubMed ID: 26959549
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Anti-Proliferative Activity of Sulfanyltriazolylnaphthalenols and Sulfanyltriazolylnaphthalene-1,4-diones.
Chaaban I; El Khawass el SM; Abd El Razik HA; El Salamouni NS; Redondo-Horcajo M; Barasoain I; Díaz JF; Yli-Kauhaluoma J; Moreira VM
Arch Pharm (Weinheim); 2016 Sep; 349(9):749-61. PubMed ID: 27404773
[TBL] [Abstract][Full Text] [Related]
15. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
16. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Yin X; Luistro L; Zhong H; Smith M; Nevins T; Schostack K; Hilton H; Lin TA; Truitt T; Biondi D; Wang X; Packman K; Rosinski J; Berkofsky-Fessler W; Tang JP; Pant S; Geho D; Vega-Harring S; Demario M; Levitsky H; Simcox M
Clin Cancer Res; 2013 Oct; 19(20):5686-98. PubMed ID: 23974006
[TBL] [Abstract][Full Text] [Related]
17. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.
Prestwich GD
Acc Chem Res; 2008 Jan; 41(1):139-48. PubMed ID: 17655274
[TBL] [Abstract][Full Text] [Related]
18. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.
Griffiths M; Sundaram H
Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428
[TBL] [Abstract][Full Text] [Related]
19. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
[TBL] [Abstract][Full Text] [Related]
20. N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells.
Wang M; Zhou A; An T; Kong L; Yu C; Liu J; Xia C; Zhou H; Li Y
J Exp Clin Cancer Res; 2016 Mar; 35():41. PubMed ID: 26940018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]